Viral Vector-Based Gene Therapy Drugs- Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Table of Contents

 1 Market Overview
    1.1 Viral Vector-Based Gene Therapy Drugs Product Introduction
    1.2 Global Viral Vector-Based Gene Therapy Drugs Market Size Forecast (2019-2030)
    1.3 Viral Vector-Based Gene Therapy Drugs Market Trends & Drivers
        1.3.1 Viral Vector-Based Gene Therapy Drugs Industry Trends
        1.3.2 Viral Vector-Based Gene Therapy Drugs Market Drivers & Opportunity
        1.3.3 Viral Vector-Based Gene Therapy Drugs Market Challenges
        1.3.4 Viral Vector-Based Gene Therapy Drugs Market Restraints
    1.4 Assumptions and Limitations
    1.5 Study Objectives
    1.6 Years Considered

 2 Competitive Analysis by Company
    2.1 Global Viral Vector-Based Gene Therapy Drugs Players Revenue Ranking (2023)
    2.2 Global Viral Vector-Based Gene Therapy Drugs Revenue by Company (2019-2024)
    2.3 Key Companies Viral Vector-Based Gene Therapy Drugs Manufacturing Base Distribution and Headquarters
    2.4 Key Companies Viral Vector-Based Gene Therapy Drugs Product Offered
    2.5 Key Companies Time to Begin Mass Production of Viral Vector-Based Gene Therapy Drugs
    2.6 Viral Vector-Based Gene Therapy Drugs Market Competitive Analysis
        2.6.1 Viral Vector-Based Gene Therapy Drugs Market Concentration Rate (2019-2024)
        2.6.2 Global 5 and 10 Largest Companies by Viral Vector-Based Gene Therapy Drugs Revenue in 2023
        2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Viral Vector-Based Gene Therapy Drugs as of 2023)
    2.7 Mergers & Acquisitions, Expansion

 3 Segmentation by Type
    3.1 Introduction by Type
        3.1.1 Retroviral Vector
        3.1.2 Adenovirus Vector
        3.1.3 Lentiviral Vector
        3.1.4 Others
    3.2 Global Viral Vector-Based Gene Therapy Drugs Sales Value by Type
        3.2.1 Global Viral Vector-Based Gene Therapy Drugs Sales Value by Type (2019 VS 2023 VS 2030)
        3.2.2 Global Viral Vector-Based Gene Therapy Drugs Sales Value, by Type (2019-2030)
        3.2.3 Global Viral Vector-Based Gene Therapy Drugs Sales Value, by Type (%) (2019-2030)

 4 Segmentation by Application
    4.1 Introduction by Application
        4.1.1 Hospital
        4.1.2 Diagnostic and Testing Laboratories
        4.1.3 Academic and Research Organizations
        4.1.4 Others
    4.2 Global Viral Vector-Based Gene Therapy Drugs Sales Value by Application
        4.2.1 Global Viral Vector-Based Gene Therapy Drugs Sales Value by Application (2019 VS 2023 VS 2030)
        4.2.2 Global Viral Vector-Based Gene Therapy Drugs Sales Value, by Application (2019-2030)
        4.2.3 Global Viral Vector-Based Gene Therapy Drugs Sales Value, by Application (%) (2019-2030)

 5 Segmentation by Region
    5.1 Global Viral Vector-Based Gene Therapy Drugs Sales Value by Region
        5.1.1 Global Viral Vector-Based Gene Therapy Drugs Sales Value by Region: 2019 VS 2023 VS 2030
        5.1.2 Global Viral Vector-Based Gene Therapy Drugs Sales Value by Region (2019-2024)
        5.1.3 Global Viral Vector-Based Gene Therapy Drugs Sales Value by Region (2025-2030)
        5.1.4 Global Viral Vector-Based Gene Therapy Drugs Sales Value by Region (%), (2019-2030)
    5.2 North America
        5.2.1 North America Viral Vector-Based Gene Therapy Drugs Sales Value, 2019-2030
        5.2.2 North America Viral Vector-Based Gene Therapy Drugs Sales Value by Country (%), 2023 VS 2030
    5.3 Europe
        5.3.1 Europe Viral Vector-Based Gene Therapy Drugs Sales Value, 2019-2030
        5.3.2 Europe Viral Vector-Based Gene Therapy Drugs Sales Value by Country (%), 2023 VS 2030
    5.4 Asia Pacific
        5.4.1 Asia Pacific Viral Vector-Based Gene Therapy Drugs Sales Value, 2019-2030
        5.4.2 Asia Pacific Viral Vector-Based Gene Therapy Drugs Sales Value by Region (%), 2023 VS 2030
    5.5 South America
        5.5.1 South America Viral Vector-Based Gene Therapy Drugs Sales Value, 2019-2030
        5.5.2 South America Viral Vector-Based Gene Therapy Drugs Sales Value by Country (%), 2023 VS 2030
    5.6 Middle East & Africa
        5.6.1 Middle East & Africa Viral Vector-Based Gene Therapy Drugs Sales Value, 2019-2030
        5.6.2 Middle East & Africa Viral Vector-Based Gene Therapy Drugs Sales Value by Country (%), 2023 VS 2030

 6 Segmentation by Key Countries/Regions
    6.1 Key Countries/Regions Viral Vector-Based Gene Therapy Drugs Sales Value Growth Trends, 2019 VS 2023 VS 2030
    6.2 Key Countries/Regions Viral Vector-Based Gene Therapy Drugs Sales Value, 2019-2030
    6.3 United States
        6.3.1 United States Viral Vector-Based Gene Therapy Drugs Sales Value, 2019-2030
        6.3.2 United States Viral Vector-Based Gene Therapy Drugs Sales Value by Type (%), 2023 VS 2030
        6.3.3 United States Viral Vector-Based Gene Therapy Drugs Sales Value by Application, 2023 VS 2030
    6.4 Europe
        6.4.1 Europe Viral Vector-Based Gene Therapy Drugs Sales Value, 2019-2030
        6.4.2 Europe Viral Vector-Based Gene Therapy Drugs Sales Value by Type (%), 2023 VS 2030
        6.4.3 Europe Viral Vector-Based Gene Therapy Drugs Sales Value by Application, 2023 VS 2030
    6.5 China
        6.5.1 China Viral Vector-Based Gene Therapy Drugs Sales Value, 2019-2030
        6.5.2 China Viral Vector-Based Gene Therapy Drugs Sales Value by Type (%), 2023 VS 2030
        6.5.3 China Viral Vector-Based Gene Therapy Drugs Sales Value by Application, 2023 VS 2030
    6.6 Japan
        6.6.1 Japan Viral Vector-Based Gene Therapy Drugs Sales Value, 2019-2030
        6.6.2 Japan Viral Vector-Based Gene Therapy Drugs Sales Value by Type (%), 2023 VS 2030
        6.6.3 Japan Viral Vector-Based Gene Therapy Drugs Sales Value by Application, 2023 VS 2030
    6.7 South Korea
        6.7.1 South Korea Viral Vector-Based Gene Therapy Drugs Sales Value, 2019-2030
        6.7.2 South Korea Viral Vector-Based Gene Therapy Drugs Sales Value by Type (%), 2023 VS 2030
        6.7.3 South Korea Viral Vector-Based Gene Therapy Drugs Sales Value by Application, 2023 VS 2030
    6.8 Southeast Asia
        6.8.1 Southeast Asia Viral Vector-Based Gene Therapy Drugs Sales Value, 2019-2030
        6.8.2 Southeast Asia Viral Vector-Based Gene Therapy Drugs Sales Value by Type (%), 2023 VS 2030
        6.8.3 Southeast Asia Viral Vector-Based Gene Therapy Drugs Sales Value by Application, 2023 VS 2030
    6.9 India
        6.9.1 India Viral Vector-Based Gene Therapy Drugs Sales Value, 2019-2030
        6.9.2 India Viral Vector-Based Gene Therapy Drugs Sales Value by Type (%), 2023 VS 2030
        6.9.3 India Viral Vector-Based Gene Therapy Drugs Sales Value by Application, 2023 VS 2030

 7 Company Profiles
    7.1 GSK
        7.1.1 GSK Profile
        7.1.2 GSK Main Business
        7.1.3 GSK Viral Vector-Based Gene Therapy Drugs Products, Services and Solutions
        7.1.4 GSK Viral Vector-Based Gene Therapy Drugs Revenue (US$ Million) & (2019-2024)
        7.1.5 GSK Recent Developments
    7.2 MolMed
        7.2.1 MolMed Profile
        7.2.2 MolMed Main Business
        7.2.3 MolMed Viral Vector-Based Gene Therapy Drugs Products, Services and Solutions
        7.2.4 MolMed Viral Vector-Based Gene Therapy Drugs Revenue (US$ Million) & (2019-2024)
        7.2.5 MolMed Recent Developments
    7.3 GILD
        7.3.1 GILD Profile
        7.3.2 GILD Main Business
        7.3.3 GILD Viral Vector-Based Gene Therapy Drugs Products, Services and Solutions
        7.3.4 GILD Viral Vector-Based Gene Therapy Drugs Revenue (US$ Million) & (2019-2024)
        7.3.5 GILD Recent Developments
    7.4 JW Therapeutics
        7.4.1 JW Therapeutics Profile
        7.4.2 JW Therapeutics Main Business
        7.4.3 JW Therapeutics Viral Vector-Based Gene Therapy Drugs Products, Services and Solutions
        7.4.4 JW Therapeutics Viral Vector-Based Gene Therapy Drugs Revenue (US$ Million) & (2019-2024)
        7.4.5 JW Therapeutics Recent Developments
    7.5 Sibiono
        7.5.1 Sibiono Profile
        7.5.2 Sibiono Main Business
        7.5.3 Sibiono Viral Vector-Based Gene Therapy Drugs Products, Services and Solutions
        7.5.4 Sibiono Viral Vector-Based Gene Therapy Drugs Revenue (US$ Million) & (2019-2024)
        7.5.5 Sibiono Recent Developments
    7.6 Latima
        7.6.1 Latima Profile
        7.6.2 Latima Main Business
        7.6.3 Latima Viral Vector-Based Gene Therapy Drugs Products, Services and Solutions
        7.6.4 Latima Viral Vector-Based Gene Therapy Drugs Revenue (US$ Million) & (2019-2024)
        7.6.5 Latima Recent Developments
    7.7 Novartis
        7.7.1 Novartis Profile
        7.7.2 Novartis Main Business
        7.7.3 Novartis Viral Vector-Based Gene Therapy Drugs Products, Services and Solutions
        7.7.4 Novartis Viral Vector-Based Gene Therapy Drugs Revenue (US$ Million) & (2019-2024)
        7.7.5 Novartis Recent Developments
    7.8 Bluebird Bio
        7.8.1 Bluebird Bio Profile
        7.8.2 Bluebird Bio Main Business
        7.8.3 Bluebird Bio Viral Vector-Based Gene Therapy Drugs Products, Services and Solutions
        7.8.4 Bluebird Bio Viral Vector-Based Gene Therapy Drugs Revenue (US$ Million) & (2019-2024)
        7.8.5 Bluebird Bio Recent Developments
    7.9 Thermo Fisher Scientific
        7.9.1 Thermo Fisher Scientific Profile
        7.9.2 Thermo Fisher Scientific Main Business
        7.9.3 Thermo Fisher Scientific Viral Vector-Based Gene Therapy Drugs Products, Services and Solutions
        7.9.4 Thermo Fisher Scientific Viral Vector-Based Gene Therapy Drugs Revenue (US$ Million) & (2019-2024)
        7.9.5 Thermo Fisher Scientific Recent Developments
    7.10 Intas
        7.10.1 Intas Profile
        7.10.2 Intas Main Business
        7.10.3 Intas Viral Vector-Based Gene Therapy Drugs Products, Services and Solutions
        7.10.4 Intas Viral Vector-Based Gene Therapy Drugs Revenue (US$ Million) & (2019-2024)
        7.10.5 Intas Recent Developments
    7.11 BMS
        7.11.1 BMS Profile
        7.11.2 BMS Main Business
        7.11.3 BMS Viral Vector-Based Gene Therapy Drugs Products, Services and Solutions
        7.11.4 BMS Viral Vector-Based Gene Therapy Drugs Revenue (US$ Million) & (2019-2024)
        7.11.5 BMS Recent Developments
    7.12 Orchard Therapeutics
        7.12.1 Orchard Therapeutics Profile
        7.12.2 Orchard Therapeutics Main Business
        7.12.3 Orchard Therapeutics Viral Vector-Based Gene Therapy Drugs Products, Services and Solutions
        7.12.4 Orchard Therapeutics Viral Vector-Based Gene Therapy Drugs Revenue (US$ Million) & (2019-2024)
        7.12.5 Orchard Therapeutics Recent Developments
    7.13 Shanghai Sunway Biotech
        7.13.1 Shanghai Sunway Biotech Profile
        7.13.2 Shanghai Sunway Biotech Main Business
        7.13.3 Shanghai Sunway Biotech Viral Vector-Based Gene Therapy Drugs Products, Services and Solutions
        7.13.4 Shanghai Sunway Biotech Viral Vector-Based Gene Therapy Drugs Revenue (US$ Million) & (2019-2024)
        7.13.5 Shanghai Sunway Biotech Recent Developments
    7.14 uniQure
        7.14.1 uniQure Profile
        7.14.2 uniQure Main Business
        7.14.3 uniQure Viral Vector-Based Gene Therapy Drugs Products, Services and Solutions
        7.14.4 uniQure Viral Vector-Based Gene Therapy Drugs Revenue (US$ Million) & (2019-2024)
        7.14.5 uniQure Recent Developments
    7.15 Spark Therapeutics
        7.15.1 Spark Therapeutics Profile
        7.15.2 Spark Therapeutics Main Business
        7.15.3 Spark Therapeutics Viral Vector-Based Gene Therapy Drugs Products, Services and Solutions
        7.15.4 Spark Therapeutics Viral Vector-Based Gene Therapy Drugs Revenue (US$ Million) & (2019-2024)
        7.15.5 Spark Therapeutics Recent Developments

 8 Industry Chain Analysis
    8.1 Viral Vector-Based Gene Therapy Drugs Industrial Chain
    8.2 Viral Vector-Based Gene Therapy Drugs Upstream Analysis
        8.2.1 Key Raw Materials
        8.2.2 Raw Materials Key Suppliers
        8.2.3 Manufacturing Cost Structure
    8.3 Midstream Analysis
    8.4 Downstream Analysis (Customers Analysis)
    8.5 Sales Model and Sales Channels
        8.5.1 Viral Vector-Based Gene Therapy Drugs Sales Model
        8.5.2 Sales Channel
        8.5.3 Viral Vector-Based Gene Therapy Drugs Distributors

 9 Research Findings and Conclusion

 10 Appendix
    10.1 Research Methodology
        10.1.1 Methodology/Research Approach
            10.1.1.1 Research Programs/Design
            10.1.1.2 Market Size Estimation
            10.1.1.3 Market Breakdown and Data Triangulation
        10.1.2 Data Source
            10.1.2.1 Secondary Sources
            10.1.2.2 Primary Sources
    10.2 Author Details
    10.3 Disclaimer

Table of Figures

List of Tables
 Table 1. Viral Vector-Based Gene Therapy Drugs Market Trends
 Table 2. Viral Vector-Based Gene Therapy Drugs Market Drivers & Opportunity
 Table 3. Viral Vector-Based Gene Therapy Drugs Market Challenges
 Table 4. Viral Vector-Based Gene Therapy Drugs Market Restraints
 Table 5. Global Viral Vector-Based Gene Therapy Drugs Revenue by Company (2019-2024) & (US$ Million)
 Table 6. Global Viral Vector-Based Gene Therapy Drugs Revenue Market Share by Company (2019-2024)
 Table 7. Key Companies Viral Vector-Based Gene Therapy Drugs Manufacturing Base Distribution and Headquarters
 Table 8. Key Companies Viral Vector-Based Gene Therapy Drugs Product Type
 Table 9. Key Companies Time to Begin Mass Production of Viral Vector-Based Gene Therapy Drugs
 Table 10. Global Viral Vector-Based Gene Therapy Drugs Companies Market Concentration Ratio (CR5 and HHI)
 Table 11. Global Top Companies Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Viral Vector-Based Gene Therapy Drugs as of 2023)
 Table 12. Mergers & Acquisitions, Expansion Plans
 Table 13. Global Viral Vector-Based Gene Therapy Drugs Sales Value by Type: 2019 VS 2023 VS 2030 (US$ Million)
 Table 14. Global Viral Vector-Based Gene Therapy Drugs Sales Value by Type (2019-2024) & (US$ Million)
 Table 15. Global Viral Vector-Based Gene Therapy Drugs Sales Value by Type (2025-2030) & (US$ Million)
 Table 16. Global Viral Vector-Based Gene Therapy Drugs Sales Market Share in Value by Type (2019-2024)
 Table 17. Global Viral Vector-Based Gene Therapy Drugs Sales Market Share in Value by Type (2025-2030)
 Table 18. Global Viral Vector-Based Gene Therapy Drugs Sales Value by Application: 2019 VS 2023 VS 2030 (US$ Million)
 Table 19. Global Viral Vector-Based Gene Therapy Drugs Sales Value by Application (2019-2024) & (US$ Million)
 Table 20. Global Viral Vector-Based Gene Therapy Drugs Sales Value by Application (2025-2030) & (US$ Million)
 Table 21. Global Viral Vector-Based Gene Therapy Drugs Sales Market Share in Value by Application (2019-2024)
 Table 22. Global Viral Vector-Based Gene Therapy Drugs Sales Market Share in Value by Application (2025-2030)
 Table 23. Global Viral Vector-Based Gene Therapy Drugs Sales Value by Region, (2019 VS 2023 VS 2030) & (US$ Million)
 Table 24. Global Viral Vector-Based Gene Therapy Drugs Sales Value by Region (2019-2024) & (US$ Million)
 Table 25. Global Viral Vector-Based Gene Therapy Drugs Sales Value by Region (2025-2030) & (US$ Million)
 Table 26. Global Viral Vector-Based Gene Therapy Drugs Sales Value by Region (2019-2024) & (%)
 Table 27. Global Viral Vector-Based Gene Therapy Drugs Sales Value by Region (2025-2030) & (%)
 Table 28. Key Countries/Regions Viral Vector-Based Gene Therapy Drugs Sales Value Growth Trends, (US$ Million): 2019 VS 2023 VS 2030
 Table 29. Key Countries/Regions Viral Vector-Based Gene Therapy Drugs Sales Value, (2019-2024) & (US$ Million)
 Table 30. Key Countries/Regions Viral Vector-Based Gene Therapy Drugs Sales Value, (2025-2030) & (US$ Million)
 Table 31. GSK Basic Information List
 Table 32. GSK Description and Business Overview
 Table 33. GSK Viral Vector-Based Gene Therapy Drugs Products, Services and Solutions
 Table 34. Revenue (US$ Million) in Viral Vector-Based Gene Therapy Drugs Business of GSK (2019-2024)
 Table 35. GSK Recent Developments
 Table 36. MolMed Basic Information List
 Table 37. MolMed Description and Business Overview
 Table 38. MolMed Viral Vector-Based Gene Therapy Drugs Products, Services and Solutions
 Table 39. Revenue (US$ Million) in Viral Vector-Based Gene Therapy Drugs Business of MolMed (2019-2024)
 Table 40. MolMed Recent Developments
 Table 41. GILD Basic Information List
 Table 42. GILD Description and Business Overview
 Table 43. GILD Viral Vector-Based Gene Therapy Drugs Products, Services and Solutions
 Table 44. Revenue (US$ Million) in Viral Vector-Based Gene Therapy Drugs Business of GILD (2019-2024)
 Table 45. GILD Recent Developments
 Table 46. JW Therapeutics Basic Information List
 Table 47. JW Therapeutics Description and Business Overview
 Table 48. JW Therapeutics Viral Vector-Based Gene Therapy Drugs Products, Services and Solutions
 Table 49. Revenue (US$ Million) in Viral Vector-Based Gene Therapy Drugs Business of JW Therapeutics (2019-2024)
 Table 50. JW Therapeutics Recent Developments
 Table 51. Sibiono Basic Information List
 Table 52. Sibiono Description and Business Overview
 Table 53. Sibiono Viral Vector-Based Gene Therapy Drugs Products, Services and Solutions
 Table 54. Revenue (US$ Million) in Viral Vector-Based Gene Therapy Drugs Business of Sibiono (2019-2024)
 Table 55. Sibiono Recent Developments
 Table 56. Latima Basic Information List
 Table 57. Latima Description and Business Overview
 Table 58. Latima Viral Vector-Based Gene Therapy Drugs Products, Services and Solutions
 Table 59. Revenue (US$ Million) in Viral Vector-Based Gene Therapy Drugs Business of Latima (2019-2024)
 Table 60. Latima Recent Developments
 Table 61. Novartis Basic Information List
 Table 62. Novartis Description and Business Overview
 Table 63. Novartis Viral Vector-Based Gene Therapy Drugs Products, Services and Solutions
 Table 64. Revenue (US$ Million) in Viral Vector-Based Gene Therapy Drugs Business of Novartis (2019-2024)
 Table 65. Novartis Recent Developments
 Table 66. Bluebird Bio Basic Information List
 Table 67. Bluebird Bio Description and Business Overview
 Table 68. Bluebird Bio Viral Vector-Based Gene Therapy Drugs Products, Services and Solutions
 Table 69. Revenue (US$ Million) in Viral Vector-Based Gene Therapy Drugs Business of Bluebird Bio (2019-2024)
 Table 70. Bluebird Bio Recent Developments
 Table 71. Thermo Fisher Scientific Basic Information List
 Table 72. Thermo Fisher Scientific Description and Business Overview
 Table 73. Thermo Fisher Scientific Viral Vector-Based Gene Therapy Drugs Products, Services and Solutions
 Table 74. Revenue (US$ Million) in Viral Vector-Based Gene Therapy Drugs Business of Thermo Fisher Scientific (2019-2024)
 Table 75. Thermo Fisher Scientific Recent Developments
 Table 76. Intas Basic Information List
 Table 77. Intas Description and Business Overview
 Table 78. Intas Viral Vector-Based Gene Therapy Drugs Products, Services and Solutions
 Table 79. Revenue (US$ Million) in Viral Vector-Based Gene Therapy Drugs Business of Intas (2019-2024)
 Table 80. Intas Recent Developments
 Table 81. BMS Basic Information List
 Table 82. BMS Description and Business Overview
 Table 83. BMS Viral Vector-Based Gene Therapy Drugs Products, Services and Solutions
 Table 84. Revenue (US$ Million) in Viral Vector-Based Gene Therapy Drugs Business of BMS (2019-2024)
 Table 85. BMS Recent Developments
 Table 86. Orchard Therapeutics Basic Information List
 Table 87. Orchard Therapeutics Description and Business Overview
 Table 88. Orchard Therapeutics Viral Vector-Based Gene Therapy Drugs Products, Services and Solutions
 Table 89. Revenue (US$ Million) in Viral Vector-Based Gene Therapy Drugs Business of Orchard Therapeutics (2019-2024)
 Table 90. Orchard Therapeutics Recent Developments
 Table 91. Shanghai Sunway Biotech Basic Information List
 Table 92. Shanghai Sunway Biotech Description and Business Overview
 Table 93. Shanghai Sunway Biotech Viral Vector-Based Gene Therapy Drugs Products, Services and Solutions
 Table 94. Revenue (US$ Million) in Viral Vector-Based Gene Therapy Drugs Business of Shanghai Sunway Biotech (2019-2024)
 Table 95. Shanghai Sunway Biotech Recent Developments
 Table 96. uniQure Basic Information List
 Table 97. uniQure Description and Business Overview
 Table 98. uniQure Viral Vector-Based Gene Therapy Drugs Products, Services and Solutions
 Table 99. Revenue (US$ Million) in Viral Vector-Based Gene Therapy Drugs Business of uniQure (2019-2024)
 Table 100. uniQure Recent Developments
 Table 101. Spark Therapeutics Basic Information List
 Table 102. Spark Therapeutics Description and Business Overview
 Table 103. Spark Therapeutics Viral Vector-Based Gene Therapy Drugs Products, Services and Solutions
 Table 104. Revenue (US$ Million) in Viral Vector-Based Gene Therapy Drugs Business of Spark Therapeutics (2019-2024)
 Table 105. Spark Therapeutics Recent Developments
 Table 106. Key Raw Materials Lists
 Table 107. Raw Materials Key Suppliers Lists
 Table 108. Viral Vector-Based Gene Therapy Drugs Downstream Customers
 Table 109. Viral Vector-Based Gene Therapy Drugs Distributors List
 Table 110. Research Programs/Design for This Report
 Table 111. Key Data Information from Secondary Sources
 Table 112. Key Data Information from Primary Sources
 Table 113. Business Unit and Senior & Team Lead Analysts


List of Figures
 Figure 1. Viral Vector-Based Gene Therapy Drugs Product Picture
 Figure 2. Global Viral Vector-Based Gene Therapy Drugs Sales Value, 2019 VS 2023 VS 2030 (US$ Million)
 Figure 3. Global Viral Vector-Based Gene Therapy Drugs Sales Value (2019-2030) & (US$ Million)
 Figure 4. Viral Vector-Based Gene Therapy Drugs Report Years Considered
 Figure 5. Global Viral Vector-Based Gene Therapy Drugs Players Revenue Ranking (2023) & (US$ Million)
 Figure 6. The 5 and 10 Largest Companies in the World: Market Share by Viral Vector-Based Gene Therapy Drugs Revenue in 2023
 Figure 7. Viral Vector-Based Gene Therapy Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
 Figure 8. Retroviral Vector Picture
 Figure 9. Adenovirus Vector Picture
 Figure 10. Lentiviral Vector Picture
 Figure 11. Others Picture
 Figure 12. Global Viral Vector-Based Gene Therapy Drugs Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)
 Figure 13. Global Viral Vector-Based Gene Therapy Drugs Sales Value Market Share by Type, 2023 & 2030
 Figure 14. Product Picture of Hospital
 Figure 15. Product Picture of Diagnostic and Testing Laboratories
 Figure 16. Product Picture of Academic and Research Organizations
 Figure 17. Product Picture of Others
 Figure 18. Global Viral Vector-Based Gene Therapy Drugs Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million)
 Figure 19. Global Viral Vector-Based Gene Therapy Drugs Sales Value Market Share by Application, 2023 & 2030
 Figure 20. North America Viral Vector-Based Gene Therapy Drugs Sales Value (2019-2030) & (US$ Million)
 Figure 21. North America Viral Vector-Based Gene Therapy Drugs Sales Value by Country (%), 2023 VS 2030
 Figure 22. Europe Viral Vector-Based Gene Therapy Drugs Sales Value, (2019-2030) & (US$ Million)
 Figure 23. Europe Viral Vector-Based Gene Therapy Drugs Sales Value by Country (%), 2023 VS 2030
 Figure 24. Asia Pacific Viral Vector-Based Gene Therapy Drugs Sales Value, (2019-2030) & (US$ Million)
 Figure 25. Asia Pacific Viral Vector-Based Gene Therapy Drugs Sales Value by Region (%), 2023 VS 2030
 Figure 26. South America Viral Vector-Based Gene Therapy Drugs Sales Value, (2019-2030) & (US$ Million)
 Figure 27. South America Viral Vector-Based Gene Therapy Drugs Sales Value by Country (%), 2023 VS 2030
 Figure 28. Middle East & Africa Viral Vector-Based Gene Therapy Drugs Sales Value, (2019-2030) & (US$ Million)
 Figure 29. Middle East & Africa Viral Vector-Based Gene Therapy Drugs Sales Value by Country (%), 2023 VS 2030
 Figure 30. Key Countries/Regions Viral Vector-Based Gene Therapy Drugs Sales Value (%), (2019-2030)
 Figure 31. United States Viral Vector-Based Gene Therapy Drugs Sales Value, (2019-2030) & (US$ Million)
 Figure 32. United States Viral Vector-Based Gene Therapy Drugs Sales Value by Type (%), 2023 VS 2030
 Figure 33. United States Viral Vector-Based Gene Therapy Drugs Sales Value by Application (%), 2023 VS 2030
 Figure 34. Europe Viral Vector-Based Gene Therapy Drugs Sales Value, (2019-2030) & (US$ Million)
 Figure 35. Europe Viral Vector-Based Gene Therapy Drugs Sales Value by Type (%), 2023 VS 2030
 Figure 36. Europe Viral Vector-Based Gene Therapy Drugs Sales Value by Application (%), 2023 VS 2030
 Figure 37. China Viral Vector-Based Gene Therapy Drugs Sales Value, (2019-2030) & (US$ Million)
 Figure 38. China Viral Vector-Based Gene Therapy Drugs Sales Value by Type (%), 2023 VS 2030
 Figure 39. China Viral Vector-Based Gene Therapy Drugs Sales Value by Application (%), 2023 VS 2030
 Figure 40. Japan Viral Vector-Based Gene Therapy Drugs Sales Value, (2019-2030) & (US$ Million)
 Figure 41. Japan Viral Vector-Based Gene Therapy Drugs Sales Value by Type (%), 2023 VS 2030
 Figure 42. Japan Viral Vector-Based Gene Therapy Drugs Sales Value by Application (%), 2023 VS 2030
 Figure 43. South Korea Viral Vector-Based Gene Therapy Drugs Sales Value, (2019-2030) & (US$ Million)
 Figure 44. South Korea Viral Vector-Based Gene Therapy Drugs Sales Value by Type (%), 2023 VS 2030
 Figure 45. South Korea Viral Vector-Based Gene Therapy Drugs Sales Value by Application (%), 2023 VS 2030
 Figure 46. Southeast Asia Viral Vector-Based Gene Therapy Drugs Sales Value, (2019-2030) & (US$ Million)
 Figure 47. Southeast Asia Viral Vector-Based Gene Therapy Drugs Sales Value by Type (%), 2023 VS 2030
 Figure 48. Southeast Asia Viral Vector-Based Gene Therapy Drugs Sales Value by Application (%), 2023 VS 2030
 Figure 49. India Viral Vector-Based Gene Therapy Drugs Sales Value, (2019-2030) & (US$ Million)
 Figure 50. India Viral Vector-Based Gene Therapy Drugs Sales Value by Type (%), 2023 VS 2030
 Figure 51. India Viral Vector-Based Gene Therapy Drugs Sales Value by Application (%), 2023 VS 2030
 Figure 52. Viral Vector-Based Gene Therapy Drugs Industrial Chain
 Figure 53. Viral Vector-Based Gene Therapy Drugs Manufacturing Cost Structure
 Figure 54. Channels of Distribution (Direct Sales, and Distribution)
 Figure 55. Bottom-up and Top-down Approaches for This Report
 Figure 56. Data Triangulation
 Figure 57. Key Executives Interviewed